Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(5); doi: 10.25236/AJMHS.2023.040503.

Potential Mechanism of Andrographolide in Coronary Heart Disease Treatment Based on Network Pharmacology and Molecular Docking


Bingshi Liu, Weichao Shan, Wenjing Zhang, Yanfang Wang

Corresponding Author:
Weichao Shan

Department of Cardiology, the Affiliated Hospital of Chengde Medical University, Chengde, Hebei, 067000, China


The potential mechanism of andrographolide in the treatment of coronary heart disease was explored through network pharmacology and molecular docking. The potential targets of andrographolide were predicted by the PharmMapper platform, and the related targets of coronary heart disease were searched using GeneCard, OMIM, and other websites. The intersection of the two was obtained to determine the common targets of andrographolide and coronary heart disease, and the common targets were analyzed. Finally, 10 core targets of andrographolide in the treatment of coronary heart disease were obtained. The PDB database was accessed to obtain the core target structure and molecular docking was performed between the core target protein structure and andrographolide structure. The structure with the largest absolute affinity was further analyzed. A total of 117 proteins were obtained as potential targets for andrographolide in the treatment of coronary heart disease. Further analysis showed that 10 proteins (IGF1, ESR1, HSP90AA1, SRC, MAPK1, MAPK8, MAPK14, PIK3R1, PTPN11 and EGFR) were obtained as core targets. After molecular docking, the above targets had high affinity for andrographolide, and andrographolide could bind to the above coronary heart disease-related proteins. Andrographolide can treat coronary heart disease through a variety of ways. This experiment verifies the potential mechanism of andrographolide in the treatment of coronary heart disease, but it still needs long-term animal and clinical trials to further verify the accuracy of this experiment.


Coronary heart disease; Andrographolide; Network pharmacology; Molecular docking; Traditional Chinese Medicine System Pharmacology

Cite This Paper

Bingshi Liu, Weichao Shan, Wenjing Zhang, Yanfang Wang. Potential Mechanism of Andrographolide in Coronary Heart Disease Treatment Based on Network Pharmacology and Molecular Docking. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 5: 10-18. https://doi.org/10.25236/AJMHS.2023.040503.


[1] Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639.

[2] Burgos RA, Alarcón P, Quiroga J, Manosalva C, Hancke J. Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism. Molecules. 2020; 26 (1):5. 

[3] Li J, Luo L, Wang X, Liao B, Li G. Inhibition of NF-kappaB expression and allergen-induced airway inflammation in a mouse allergic asthma model by andrographolide. Cell Mol Immunol. 2009;6(5):381–85.

[4] Lien LM, Su CC, Hsu WH, et al. Mechanisms of andrographolide-induced platelet apoptosis in human platelets: regulatory roles of the extrinsic apoptotic pathway. Phytother Res. 2013;27(11):1671-7.

[5] Nie X, Shen C, Tan J, et al. Andrographolide Attenuates Established Pulmonary Hy- pertension via Rescue of Vascular Remodeling. Biomolecules. 2021;11(12):1801.

[6] Paul S, Roy D, Pati S, Sa G. The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer. Front Pharmacol. 2021;12:731492.

[7] Mishra A, Shaik HA, Sinha RK, Shah BR. Andrographolide: A Herbal- Chemosynthetic Approach for Enhancing Immunity, Combating Viral Infections, and Its Implication on Human Health. Molecules. 2021; 26(22): 7036.

[8] Zhang L, Bao M, Liu B, et al. Effect of Andrographolide and Its Analogs on Bacterial Infection: A Review. Pharmacology. 2020; 105(3-4):123–34.

[9] Ren J, Liu Z, Wang Q, et al. Andrographolide Ameliorates Abdominal Aortic Aneurysm Progression by Inhibiting Inflammatory Cell Infiltration through Downregulation of Cytokine and Integrin Expression. J Pharmacol Exp Ther. 2016; 356(1):137–47.

[10] Wang X, Shen Y, Wang S, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45[W1]: W356-W360.

[11] UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021; 49[D1]:D480-D489.

[12] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284–7.

[13] Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets [published correction appears in Nucleic Acids Res. 2021 Oct 11;49(18)10800]. Nucleic Acids Res. 2021; 49[D1]: D605-D612.

[14] Gaillard T. Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark. J Chem Inf Model. 2018; 58[8]:1697–706.

[15] Schöning-Stierand K, Diedrich K, Fährrolfes R, et al. ProteinsPlus: interactive analysis of protein-ligand binding interfaces. Nucleic Acids Res. 2020; 48[W1]:W48-W53.

[16] Dai L, Lu A, Zhong LLD, Zheng G, Bian Z. Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016. Curr Vasc Pharmacol. 2017; 15(6):520-531.

[17] Handa SS, Sharma A. Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. Indian J Med Res. 1990; 92: 276–83.

[18] Banerjee M, Chattopadhyay S, Choudhuri T, et al. Cytotoxicity and cell cycle arrest induced by andrographolide lead to programmed cell death of MDA-MB-231 breast cancer cell line. J Biomed Sci. 2016; 23:40.

[19] Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men. J Clin Endocrinol Metab. 2014;99(11):E2308-E2316.

[20] Muniyappa R, Walsh MF, Rangi JS, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997;61 (9):925-31.

[21] Liu K, Ying Z, Qi X, Shi Y, Tang Q. MicroRNA-1 regulates the proliferation of vascular smooth muscle cells by targeting insulin-like growth factor 1. Int J Mol Med. 2015;36 (3):817–24.

[22] Pan Z, Sun X, Ren J, et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. PLoS One. 2012;7 (11):e50515.

[23] Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 [HSP90] as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011;152 (4):367–79.

[24] Zhai Y, Yang J, Zhang J, Yang J, Li Q, Zheng T. Src-Family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases. Int J Med Sci. 2021;18 (5):1216-24.

[25] Quan GH, Wang H, Cao J, et al. Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB. Int J Mol Sci. 2015;16 (12):29496–507.

[26] Cheng F, Twardowski L, Fehr S, et al. Selective p38α MAP kinase/MAPK14 inhibition in enzymatically modified LDL-stimulated human monocytes: implications for atherosclerosis. FASEB J. 2017; 31(2):674–86.

[27] Zhan H, Huang F, Niu Q, et al. Downregulation of miR-128 Ameliorates Ang II-Induced Cardiac Remodeling via SIRT1/PIK3R1 Multiple Targets. Oxid Med Cell Longev. 2021;2021:8889195.

[28] Lauriol J, Kontaridis MI. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med. 2011; 21(4):97–104.

[29] Gao LB, Zhou B, Zhang L, et al. R497K polymorphism in epidermal growth factor receptor gene is associated with the risk of acute coronary syndrome. BMC Med Genet. 2008;9:74.

[30] Patel CN, Kumar SP, Pandya HA, Rawal RM. Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. Mol Divers. 2021; 25(1):421–33.